| abstract |
The present invention relates to the field of biomedicine, in particular to macrocyclic compounds, that is, compounds of general formula (I) and pharmaceutically acceptable equivalents or salts: The present invention also relates to a preparation process having the general formula (I). The present invention also provides the use of this new pyrimidine compound, specifically as a Janus kinase inhibitor, including but not limited to polycythemia vera, spontaneous thrombocytosis, chronic idiopathic myelofibrosis , myelogenous transformation with myelofibrosis, chronic idiopathic leukemia, chronic myelomonocytic leukemia, allergies, asthma, autoimmune diseases such as suppression of transplant rejection, rheumatoid arthritis, muscular contractile lateralis Sclerosis and multiple sclerosis as well as solid and hematological malignancies such as leukemia, lymphoma, etc. |